Denmark

Leo Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

Lead Product(s): Lenadogene nolparvovec

Therapeutic Area: Genetic Disease Product Name: Lumevoq

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2021

Details:

Journal of the American Academy of Ophthalmology, Ophthalmology®, has published results from the RESCUE pivotal Phase III clinical trial of LUMEVOQ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects.

Genmab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Janssen Submitts a Type II Variation Application to the EMA for Use Of Subcutaneous DARZALEX® in Patients with Light-Chain Amyloidosis

Lead Product(s): Daratumumab,Hyaluronidase,Cyclophosphamide

Therapeutic Area: Genetic Disease Product Name: Darzalex

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Janssen Pharmaceutical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 05, 2020

Details:

The submission is based on the Phase 3 ANDROMEDA study of daratumumab and hyaluronidase-fihj in combination with VCd as treatment for patients with newly diagnosed AL amyloidosis.